Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Blood Advances|December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Blood Cancer Journal|February 5, 2025
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestryCecilia Bonolo de Campos, Chantal E McCabe, Laura A Bruins, et al.
Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Leukemia|July 21, 2021
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African AmericansGeffen Kleinstern, J Brice Weinberg, Sameer A Parikh, et al.
Pageof 5